Restoration‐based strategies should be prioritized in tumours with recoverable MHC expression, while bypass strategies may be better suited for MHC‐deficient tumours refractory to reprogramming, thus maximizing therapeutic efficacy through precision‐guided immune intervention. Here, HLA-C is linked to neoplasm.